Related Experiment Video
Updated: Mar 28, 2026
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma
Mami Adachi1, Yuki Hoshino, Yusuke Izumi
1Laboratory of Advanced Veterinary Medicine, Department of Veterinary Clinical Sciences, Hokkaido University, Hokkaido 060-0818, Japan.
Abstract:
Canine hemangiosarcoma (HSA) is a progressive malignant neoplasm of dogs for which there is currently no effective treatment. A recent study suggested that receptor tyrosine kinases (RTKs), the PI3K/Akt/m-TOR and MAPK pathways are all activated in canine and human HSA. The aim of the present study was to investigate the overexpression of these proteins by immunohistochemistry in canine splenic HSA to identify potential molecular therapeutic targets. A total of 10 splenic HSAs and two normal splenic samples surgically resected from dogs were sectioned and stained with hematoxylin and eosin for histological diagnosis or analyzed using immunohistochemistry. The expression of RTKs, c-kit, VEGFR-2 and PDGFR-2, as well as PI3K/Akt/m-TOR and MEK was higher in canine splenic HSAs compared to normal spleens. These proteins may therefore be potential therapeutic targets in canine splenic HSA.
Insights
Canine hemangiosarcoma (HSA) treatment is lacking. This study found that key proteins in receptor tyrosine kinase (RTK) and PI3K/Akt/m-TOR pathways are overexpressed in canine splenic HSA, suggesting potential therapeutic targets.
Area of Science:
- Veterinary Oncology
- Molecular Pathology
- Canine Cancer Research
Background:
- Canine hemangiosarcoma (HSA) is an aggressive cancer with no effective treatments.
- Signaling pathways like receptor tyrosine kinases (RTKs), PI3K/Akt/m-TOR, and MAPK are implicated in both canine and human HSA.
Purpose of the Study:
- To investigate the overexpression of specific proteins within these pathways in canine splenic HSA.
- To identify potential molecular targets for future canine hemangiosarcoma therapies.
Main Methods:
- Immunohistochemistry was used to analyze protein expression in 10 canine splenic HSA samples and 2 normal spleens.
- Histological diagnosis was confirmed using hematoxylin and eosin staining.
Main Results:
- Overexpression of RTKs (c-kit, VEGFR-2, PDGFR-2), PI3K/Akt/m-TOR, and MEK proteins was observed in canine splenic HSAs compared to normal tissues.
- Elevated expression suggests these proteins are involved in HSA development.
Conclusions:
- The identified overexpressed proteins represent promising molecular targets for developing novel therapeutic strategies against canine splenic hemangiosarcoma.
- Further research into targeting these pathways could lead to effective treatments for canine HSA.
